Supplied as raw material only — pharmaceutical (API) and food grade.
CAS 616-91-1 · ChP, USP, EP, BP, AJI · GMP
ViewCAS 52-90-4 · AJI, JP
ViewCAS 7048-04-6 · CP, EP, USP, AJI
ViewCAS 638-23-3 · EP, CP, JP
ViewCAS 56-89-3 · AJI, FCC
View25+ grades · custom synthesis & tech transfer
ViewSupplied as a white crystalline powder in pharmaceutical (API) and food grades. Every batch is released with a Certificate of Analysis and is traceable to synthesis and QC records.
| CAS No. | 616-91-1 |
|---|---|
| Molecular formula | C5H9NO3S |
| Molecular weight | 163.20 g/mol |
| Pharmacopoeia | ChP · USP · EP · BP · AJI |
| Grade | Pharmaceutical (API) · Food grade |
| Appearance | White crystalline powder |
| Assay | Within current pharmacopoeia limits |
| Packing | 25 kg fibre drum (PE liner) |
| Documents | COA · MSDS · DMF · WC · COPP |
Listed with status, so you know exactly what exists today and what is in progress.
National High-Tech Enterprise (GR202533008197)
Zhejiang "SRDI" (Specialized & Innovative) SMECertificates not held or no longer valid are not listed. Items under application are marked as such.
Leading pharmaceutical companies across South Asia source NAC and amino acid APIs from our GMP production base.
Company names are shown for reference only and do not imply endorsement or an active contract.
Every figure below can be verified against a document. We would rather show certificates than adjectives.
Capacity, facilities and certifications listed above are held by Zhejiang Hichi Pharmaceutical Co., Ltd., our manufacturing base. Zhejiang Sino Hichi Pharmaceutical Co., Ltd. is its sales entity for N-acetylcysteine.
Completed product registrations for iodixanol and iohexol — evidence that this plant is regularly inspected by foreign authorities.
A five-day on-site GMP inspection by Brazil's ANVISA was closed with zero deficiencies. Together with EU GMP and the Written Confirmation, it is the fastest way for a new buyer to judge whether our manufacturing base can hold your specification.
Source: announcement 2025-023 of Zhejiang Hichi Pharmaceutical (NEEQ: 834402) and announcement 2025-097 of Beijing Beilu Pharmaceutical (300016), both dated 2 September 2025. Certificate holder: Zhejiang Hichi Pharmaceutical Co., Ltd. – our manufacturing base.
The sales company of Zhejiang Hichi Pharmaceutical Co., Ltd. – listed on China's NEEQ (834402) and controlled by Beijing Beilu Pharmaceutical (Shenzhen ChiNext: 300016).
We are a real manufacturer, not a trading desk. Customer audits, third-party audits and remote documentation reviews are all accepted.
Please notify us at least two weeks in advance so we can reserve the line, the QC centre and the responsible engineers.
Book an AuditA 4.98-hectare site (49,767 m²) with 47,518 m² of total floor area · CNY 490 million invested.
Exhibitions, technical notes and regulatory updates.
Tell us grade, pharmacopoeia, quantity and destination. We reply with COA sample, MSDS and a price proposal.
